A Phase 2 interventional study of GSK3228836 and PegIFN in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 49 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-02.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · GlaxoSmithKline.
Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 17th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2021, is one of 5 in phase 2, and was the 24th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline is open now. Recruiting first, the newest first:
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 8 · Phase 4 10
First in 2000; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 163 across the 28 interventional studies, 172 across the 2 observational. Of the 28 that completed or were terminated, 18 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Hepatitis B, Chronic by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is intended to evaluate if 12 or 24 weeks of treatment with GSK3228836 followed by up to 24 weeks of pegylated interferon (PegIFN) can increase the rate of hepatitis B virus surface antigen (HBsAg) loss in participants on stable nucleos(t)ide analogue (NA) therapy, and whether virologic response can be sustained once PegIFN treatment is discontinued. Participants will be randomized to receive GSK3228836 for 12 or 24 weeks followed by up to 24 weeks of PegIFN.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
This study's enrollment of 108 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Browse Hepatitis B, Chronic studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants on stable NA therapy received 300 milligrams per week (mg/week) GSK3228836 for 24 weeks (plus a loading dose on Day 4 and 11), followed by Pegylated Interferon (PegIFN) 180 microgram per week (mcg/week) up to 24 weeks.
Drug: GSK3228836 · Drug: PegIFN · Drug: NA therapy
Participants on stable NA therapy received 300mg/week GSK3228836 for 12 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 mcg/week up to 24 weeks.
Drug: GSK3228836 · Drug: PegIFN · Drug: NA therapy
Participants will be administered GSK3228836.
Participants will be administered PegIFN.
Participants will continue to receive their NA therapy for the duration of the study.
Treatment Arm 1 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment
Sustained virologic response is defined as undetectable levels of Hepatitis B surface antigen (HBsAg) and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as HBsAg and HBV DNA levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of sequential treatment of GSK3228836 and PegIFN treatment which is sustained for 24 weeks post-GSK3228836 and PegIFN treatment in the absence of any rescue medication. Percentage values are rounded-off.
Time frame: Up to 24 weeks off treatment (Study Weeks 48 to 72)
Treatment Arm 2 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment
Sustained virologic response is defined as undetectable levels of Hepatitis B surface antigen (HBsAg) and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as HBsAg and HBV DNA levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of sequential treatment of GSK3228836 and PegIFN treatment which is sustained for 24 weeks post-GSK3228836 and PegIFN treatment in the absence of any rescue medication. Percentage values are rounded-off.
Time frame: Up to 24 weeks off treatment (Study Weeks 36 to 60)
Treatment Arm 1: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ)
Percentage of participants achieving HBsAg and HBV DNA \<LLOQ were reported. Percentage values are rounded-off.
Time frame: End of treatment (up to 48 weeks) and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ)
Percentage of participants achieving HBsAg and HBV DNA \<LLOQ were reported. Percentage values are rounded-off.
Time frame: End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values
Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from baseline values. Percentage values are rounded-off.
Time frame: Baseline, End of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values
Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from baseline values. Percentage values are rounded-off.
Time frame: Baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Number of Participants With Alanine Aminotransferase (ALT) Normalization
The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.
Time frame: At baseline, end of treatment (up to 48 weeks) and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Number of Participants With Alanine Aminotransferase (ALT) Normalization
The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.
Time frame: At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Number of Participants With HBe Antibody (Anti-HBeAg) Levels
Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Number of Participants With HBe Antibody (Anti-HBeAg) Levels
Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants.
Time frame: At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Mean Change From Baseline in HBe Antibody Levels
Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Mean Change From Baseline in HBe Antibody Levels
Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Actual Values of HBsAg Levels
Blood samples were collected from participants to assess HBsAg at indicated time points.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Actual Values of HBsAg Levels
Blood samples were collected from participants to assess HBsAg at indicated time points.
Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Mean Change From Baseline in HBsAg Levels
Blood samples were collected to assess HBsAg change from baselines levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Mean Change From Baseline in HBsAg Levels
Blood samples were collected to assess HBsAg change from baselines levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Actual Values of HBV DNA Levels
Blood samples were collected to assess HBV DNA levels.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Actual Values of HBV DNA Levels
Blood samples were collected to assess HBV DNA levels.
Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Mean Change From Baseline in HBV DNA Levels
Blood samples were collected to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Mean Change From Baseline in HBV DNA Levels
Blood samples were collected to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Actual Values of Hepatitis B Virus E-antigen (HBeAg) Levels
Blood samples were collected to assess HBeAg levels.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Actual Values of Hepatitis B Virus E-antigen (HBeAg) Levels
Blood samples were collected to assess HBeAg levels.
Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Mean Change From Baseline in HBeAg Levels
Blood samples were collected to assess HBeAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Mean Change From Baseline in HBeAg Levels
Blood samples were collected to assess HBeAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Actual Values of HBs Antibody Levels
Blood samples were collected to assess HBs antibody levels.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Actual Values of HBs Antibody Levels
Blood samples were collected to assess HBs antibody levels.
Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Mean Change From Baseline in HBs Antibody Levels
Blood samples were collected to assess HBs antibody levels over time. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Mean Change From Baseline in HBs Antibody Levels
Blood samples were collected to assess HBs antibody levels over time. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Actual Values of ALT
Blood samples were collected to assess ALT mean values.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Actual Values of ALT
Blood samples were collected to assess ALT mean values.
Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1: Change From Baseline in ALT
Blood samples were collected to assess ALT values. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)
Treatment Arm 2: Change From Baseline in ALT
Blood samples were collected to assess ALT values. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)
Treatment Arm 1 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment
Time to ALT normalization in absence of rescue medication were measured in participants having Baseline ALT\>ULN.
Time frame: Up to 24 weeks off treatment (Study Week 48 to72)
Treatment Arm 2 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment
Time to ALT normalization in absence of rescue medication were measured in participants having Baseline ALT\>ULN.
Time frame: Up to 24 weeks off treatment (Study Weeks 36 to 60)
Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks Off Treatment for Comparison of Efficacy Between Different Treatment Durations
Sustained virologic response is defined as undetectable levels of HBsAg and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as Hepatitis B surface antigen (HBsAg) and Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of GSK3228836 treatment which is sustained for 24 weeks post-GSK3228836 treatment in the absence of rescue medication. The point estimate for the difference in SVR and its respective credible interval (CI) were evaluated at 24 weeks off of planned treatment for both arms. The comparison of efficacy is between treatment durations and timepoint corresponds to Week 72 in Arm 1 and Week 60 in Arm 2. 95% CI here refers as credible interval. Percentage values are rounded-off.
Time frame: Up to 24 weeks off treatment (Treatment Arm 1: Study Weeks 48 to 72 and Treatment Arm 2: Study Weeks 36 to 60)
A total of 108 participants were enrolled in this study.
| Milestone | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|---|
| Started | 55 | 53 |
| Completed | 49 | 50 |
| Not completed | 6 | 3 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 |
Sustained virologic response is defined as undetectable levels of Hepatitis B surface antigen (HBsAg) and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as HBsAg and HBV DNA levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of sequential treatment of GSK3228836 and PegIFN treatment which is sustained for 24 weeks post-GSK3228836 and PegIFN treatment in the absence of any rescue medication. Percentage values are rounded-off.
| Percentage of Participants | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| Treatment Arm 1 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment | 9 |
Sustained virologic response is defined as undetectable levels of Hepatitis B surface antigen (HBsAg) and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as HBsAg and HBV DNA levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of sequential treatment of GSK3228836 and PegIFN treatment which is sustained for 24 weeks post-GSK3228836 and PegIFN treatment in the absence of any rescue medication. Percentage values are rounded-off.
| Percentage of Participants | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| Treatment Arm 2 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment | 15 |
Percentage of participants achieving HBsAg and HBV DNA \<LLOQ were reported. Percentage values are rounded-off.
| Percentage of Participants | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of treatment (up to 48 weeks) | 15 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 13 |
Percentage of participants achieving HBsAg and HBV DNA \<LLOQ were reported. Percentage values are rounded-off.
| Percentage of Participants | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of treatment (up to 36 weeks) | 15 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 17 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 15 |
Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from baseline values. Percentage values are rounded-off.
| Percentage of Participants | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| HBsAg <LLOQ - End of Treatment (up to 48 weeks) | 18 |
| HBsAg<LLOQ - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 13 |
| HBsAg decline <0.5 - End of Treatment (up to 48 weeks) | 24 |
| HBsAg decline <0.5- Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 45 |
| HBsAg decline >=0.5 - End of Treatment (up to 48 weeks) | 42 |
| HBsAg decline >=0.5 - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 44 |
| HBsAg decline >=1 - End of Treatment (up to 48 weeks) | 33 |
| HBsAg decline >=1- Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 36 |
| HBsAg decline >=1.5 - End of Treatment (up to 48 weeks) | 27 |
| HBsAg decline >=1.5 - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 36 |
| HBsAg decline >=3 - End of Treatment (up to 48 weeks) | 20 |
| HBsAg decline >=3 - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 27 |
Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from baseline values. Percentage values are rounded-off.
| Percentage of Participants | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| HBsAg <LLOQ - End of Treatment (up to 36 weeks) | 15 |
| HBsAg<LLOQ - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 17 |
| HBsAg <LLOQ - Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 15 |
| HBsAg decline <0.5 - End of Treatment (up to 36 weeks) | 26 |
| HBsAg decline <0.5 - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 42 |
| HBsAg decline <0.5 - Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 43 |
| HBsAg decline >=0.5 - End of Treatment (up to 36 weeks) | 42 |
| HBsAg decline >=0.5 - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 51 |
| HBsAg decline >=0.5 - Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 47 |
| HBsAg decline >=1 - End of Treatment (up to 36 weeks) | 34 |
| HBsAg decline >=1 - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 34 |
| HBsAg decline >=1 - Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 32 |
| HBsAg decline >=1.5 - End of Treatment (up to 36 weeks) | 28 |
| HBsAg decline >=1.5 - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 23 |
| HBsAg decline >=1.5-up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 19 |
| HBsAg decline >=3 - End of Treatment (up to 36 weeks) | 15 |
| HBsAg decline >=3 - Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 17 |
| HBsAg decline >=3 - Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 17 |
The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.
| Participants | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| ALT>ULN, At Baseline | 4 |
| ALT normalization, End of Treatment (up to 48 weeks) | 0 |
| ALT normalization, Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 2 |
The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.
| Participants | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| ALT>ULN, At Baseline | 10 |
| ALT normalization, End of Treatment (up to 36 weeks) | 1 |
| ALT normalization, Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 5 |
| ALT normalization, Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 6 |
Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants.
| Participants | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 2 |
| End of Treatment (up to 48 weeks) | 5 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 4 |
Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants.
| Participants | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 1 |
| End of Treatment (up to 36 weeks) | 1 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 1 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 0 |
Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/mL | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of Treatment (up to 48 weeks) | -1.04 ± 1.133 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | -0.81 ± 1.044 |
Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/mL | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of Treatment (up to 36 weeks) | -0.52 ± 0.598 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | -0.58 ± 0.766 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | -0.65 ± 0.787 |
Blood samples were collected from participants to assess HBsAg at indicated time points.
| Log10 IU/mL | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 3.34 ± 0.555 |
| End of Treatment (up to 48 weeks) | 1.52 ± 2.071 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 1.72 ± 2.043 |
Blood samples were collected from participants to assess HBsAg at indicated time points.
| Log10 IU/mL | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 3.32 ± 0.622 |
| End of Treatment (up to 36 weeks) | 1.70 ± 1.896 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 2.12 ± 1.827 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 2.12 ± 1.830 |
Blood samples were collected to assess HBsAg change from baselines levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/mL | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of Treatment (up to 48 weeks) | -1.76 ± 1.726 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | -1.58 ± 1.722 |
Blood samples were collected to assess HBsAg change from baselines levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/mL | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of Treatment (up to 36 weeks) | -1.54 ± 1.567 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | -1.20 ± 1.458 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | -1.20 ± 1.460 |
Blood samples were collected to assess HBV DNA levels.
| Log10 IU/mL | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 0.64 ± 0.796 |
| End of Treatment (up to 48 weeks) | 0.97 ± 0.629 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 0.17 ± 0.438 |
Blood samples were collected to assess HBV DNA levels.
| Log10 IU/mL | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 0.57 ± 0.687 |
| End of treatment (up to 36 weeks) | 0.70 ± 0.700 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 0.34 ± 0.579 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 0.35 ± 0.587 |
Blood samples were collected to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/mL | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of treatment (up to 48 weeks) | 0.40 ± 0.945 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | -0.39 ± 0.727 |
Blood samples were collected to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/mL | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of Treatment (up to 36 weeks) | 0.21 ± 0.925 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | -0.21 ± 0.876 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | -0.22 ± 0.754 |
Blood samples were collected to assess HBeAg levels.
| Log10 IU/mL | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 14.221 ± 69.3438 |
| End of Treatment (up to 48 weeks) | 0.250 ± 0.4193 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 1.197 ± 2.4945 |
Blood samples were collected to assess HBeAg levels.
| Log10 IU/mL | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 8.510 ± 42.1588 |
| End of Treatment (up to 36 weeks) | 3.008 ± 6.2682 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 3.410 ± 6.0421 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 2.797 ± 4.8973 |
Blood samples were collected to assess HBeAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/mL | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of Treatment (up to 48 weeks) | -21.774 ± 65.4276 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | -19.482 ± 55.1948 |
Blood samples were collected to assess HBeAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/mL | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of Treatment (up to 36 weeks) | -5.270 ± 8.8942 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | -26.384 ± 80.2108 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | -26.345 ± 77.2836 |
Blood samples were collected to assess HBs antibody levels.
| Log10 IU/L | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 0.62 ± 0.271 |
| End of Treatment (up to 48 weeks) | 1.06 ± 0.903 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 0.82 ± 0.718 |
Blood samples were collected to assess HBs antibody levels.
| Log10 IU/L | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 0.69 ± 0.204 |
| End of Treatment (up to 36 weeks) | 0.87 ± 0.491 |
| Up to 24 weeks off treatment follow-up (study week 36 to week 60) | 0.80 ± 0.521 |
| Up to 36 weeks off treatment follow-up (study week 36 to week 72) | 0.76 ± 0.481 |
Blood samples were collected to assess HBs antibody levels over time. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/L | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of treatment (up to 48 weeks) | 0.42 ± 0.934 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 0.18 ± 0.757 |
Blood samples were collected to assess HBs antibody levels over time. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/L | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of Treatment (up to 36 weeks) | 0.18 ± 0.450 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 0.09 ± 0.487 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 0.05 ± 0.453 |
Blood samples were collected to assess ALT mean values.
| International Units Per Liter (IU/L) | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 22.7 ± 13.97 |
| End of Treatment (up to 48 weeks) | 53.1 ± 60.61 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 19.2 ± 9.77 |
Blood samples were collected to assess ALT mean values.
| IU/L | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| At Baseline | 26.9 ± 19.16 |
| End of Treatment (up to 36 weeks) | 55.3 ± 46.60 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 22.1 ± 13.30 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 23.5 ± 15.61 |
Blood samples were collected to assess ALT values. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| IU/L | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of Treatment (up to 48 weeks) | 27.6 ± 56.05 |
| Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | -3.8 ± 9.86 |
Blood samples were collected to assess ALT values. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| IU/L | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| End of treatment (up to 36 weeks) | 27.8 ± 40.55 |
| Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | -4.3 ± 17.50 |
| Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | -3.1 ± 18.65 |
Time to ALT normalization in absence of rescue medication were measured in participants having Baseline ALT\>ULN.
| Weeks | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| Treatment Arm 1 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment | NA (6.3 to NA) |
Time to ALT normalization in absence of rescue medication were measured in participants having Baseline ALT\>ULN.
| Weeks | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|
| Treatment Arm 2 - Median Time to ALT Normalization in Absence of Rescue Medication for 24 Weeks After End of Treatment | 4.1 (1.1 to 47.1) |
Sustained virologic response is defined as undetectable levels of HBsAg and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as Hepatitis B surface antigen (HBsAg) and Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of GSK3228836 treatment which is sustained for 24 weeks post-GSK3228836 treatment in the absence of rescue medication. The point estimate for the difference in SVR and its respective credible interval (CI) were evaluated at 24 weeks off of planned treatment for both arms. The comparison of efficacy is between treatment durations and timepoint corresponds to Week 72 in Arm 1 and Week 60 in Arm 2. 95% CI here refers as credible interval. Percentage values are rounded-off.
| Percentage of participants | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|---|
| Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks Off Treatment for Comparison of Efficacy Between Different Treatment Durations | 9 | 15 |
Collected over Up to Week 72. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 0/55 (0%) | 6/55 (10.9%) | 52/55 (94.5%) |
| GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 0/53 (0%) | 2/53 (3.8%) | 50/53 (94.3%) |
| Event | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|---|
| Peritonsillar abscessInfections and infestations | 0/55 | 1/53 |
| Spinal stenosisMusculoskeletal and connective tissue disorders | 0/55 | 1/53 |
| CholecystitisHepatobiliary disorders | 1/55 | 0/53 |
| CholelithiasisHepatobiliary disorders | 1/55 | 0/53 |
| Drug-induced liver injuryHepatobiliary disorders | 1/55 | 0/53 |
| AppendicitisInfections and infestations | 1/55 | 0/53 |
| COVID-19Infections and infestations | 1/55 | 0/53 |
| Chest injuryInjury, poisoning and procedural complications | 1/55 | 0/53 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/55 | 0/53 |
| Event | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 23/55 | 6/53 |
| Injection site erythemaGeneral disorders | 20/55 | 22/53 |
| PyrexiaGeneral disorders | 17/55 | 14/53 |
| Aspartate aminotransferase increasedInvestigations | 16/55 | 6/53 |
| COVID-19Infections and infestations | 15/55 | 5/53 |
| ThrombocytopeniaBlood and lymphatic system disorders | 14/55 | 11/53 |
| Neutrophil count decreasedInvestigations | 14/55 | 8/53 |
| NeutropeniaBlood and lymphatic system disorders | 10/55 | 12/53 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/55 | 12/53 |
| HeadacheNervous system disorders | 7/55 | 12/53 |
| Age, Continuous(YEARS) | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | Total |
|---|---|---|---|
| Mean | 45.5 ± 10.73 | 45.5 ± 9.35 | 45.5 ± 10.03 |
| Sex: Female, Male(Participants) | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | Total |
|---|---|---|---|
| Female | 11 | 20 | 31 |
| Male | 44 | 33 | 77 |
| Race/Ethnicity, Customized(Participants) | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | Total |
|---|---|---|---|
| ASIAN | 30 | 26 | 56 |
| BLACK OR AFRICAN AMERICAN | 3 | 3 | 6 |
| WHITE | 22 | 24 | 46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jan 2021 to primary completion in Feb 2023, 24 months.
Results were first posted in May 2024, 1 year 2 months after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 24 months is close to that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bepirovirsen